News | July 31, 2021
Zydus Cadila receives approval from USFDA for Fulvestrant Injection
The group now has 320 approvals and has so far filed over 400 ANDAs
The group now has 320 approvals and has so far filed over 400 ANDAs
The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
The contribution of Wockhardt at Wrexham is one of the best examples of the success and significant potential of India-UK partnerships in the healthcare sector
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
The Cephalosporin Injectables plant has a total capacity of 26.4 million vials per year while Ethiopia is having a demand for 16 million vials
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
The company is confident of commencing production at both Mahad and Chiplun units soon
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
